Cargando…

Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report

BACKGROUND: Radiation recall gastritis is rare but can be induced after concurrent chemoradiation for pancreatic cancer. We report a patient with pancreatic cancer who developed radiation-recall gastritis related to a combination of gemcitabine and erlotinib. CASE PRESENTATION: A 54-year-old female...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Seong Ji, Kim, Hyo Jung, Kim, Jae Seon, Bak, Young-Tae, Kim, Jun Suk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4971692/ https://www.ncbi.nlm.nih.gov/pubmed/27484349 http://dx.doi.org/10.1186/s12885-016-2616-3

Ejemplares similares

A phase II study of gemcitabine, erlotinib and S-1 in patients with advanced pancreatic cancer
por: Han, Boram, et al.
Publicado: (2021)

Gemcitabine Combined with Capecitabine Compared to Gemcitabine with or without Erlotinib as First-Line Chemotherapy in Patients with Advanced Pancreatic Cancer
por: Lim, Jae Yun, et al.
Publicado: (2015)

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
por: Lim, Sung Hee, et al.
Publicado: (2021)

Erlotinib plus gemcitabine versus gemcitabine for pancreatic cancer: real-world analysis of Korean national database
por: Shin, Sangjin, et al.
Publicado: (2016)

A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance)
por: Halfdanarson, Thorvardur R., et al.
Publicado: (2019)

Gemcitabine-Induced Radiation Recall Myositis: Case Report and Review of the Literature
por: Ravishankar, Adarsh, et al.
Publicado: (2018)

Erlotinib Induced Trichomegaly of the Eyelashes
por: Jeon, Sang-Hoon, et al.
Publicado: (2013)

Gemcitabine Plus Erlotinib for Advanced Pancreatic Cancer: A Systematic Review with Meta-Analysis
por: Yang, Zu-Yao, et al.
Publicado: (2013)

Integrated experimental and simulation study of the response to sequential treatment with erlotinib and gemcitabine in pancreatic cancer
por: Ubezio, Paolo, et al.
Publicado: (2016)

Concomitant Statin Use Has a Favorable Effect on Gemcitabine-Erlotinib Combination Chemotherapy for Advanced Pancreatic Cancer
por: Moon, Do Chang, et al.
Publicado: (2016)

Gemcitabine-Induced Radiation Recall Phenomenon in Cervical Cancer: A Case Report
por: Carvalho, Jesus Paula, et al.
Publicado: (2023)

Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis
por: Furuse, Junji, et al.
Publicado: (2017)

Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine
por: Kim, Tae Hwan, et al.
Publicado: (2017)

Phase II Trial of Erlotinib Plus Gemcitabine Chemotherapy in Korean Patients with Advanced Pancreatic Cancer and Prognostic Factors for Chemotherapeutic Response
por: Park, Semi, et al.
Publicado: (2013)

Phase I Evaluation of Intravenous Ascorbic Acid in Combination with Gemcitabine and Erlotinib in Patients with Metastatic Pancreatic Cancer
por: Monti, Daniel A., et al.
Publicado: (2012)

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
por: Van Cutsem, E, et al.
Publicado: (2014)

Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway
por: Chen, Liwen, et al.
Publicado: (2018)

Molecular Subgroup Analysis of Clinical Outcomes in a Phase 3 Study of Gemcitabine and Oxaliplatin with or without Erlotinib in Advanced Biliary Tract Cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Radiation recall dermatitis triggered by sorafenib after radiation therapy for hepatocellular carcinoma
por: Kim, Gwi Eon, et al.
Publicado: (2017)

Radiation Recall Dermatitis after Treatment with Paclitaxel and Cisplatin
por: Baek, Seung Woo, et al.
Publicado: (2012)

SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer
por: Kim, Myeong Jin, et al.
Publicado: (2023)

A phase I/II study of ivaltinostat combined with gemcitabine and erlotinib in patients with untreated locally advanced or metastatic pancreatic adenocarcinoma
por: Jo, Jung Hyun, et al.
Publicado: (2022)

A Phase II Trial of Gemcitabine plus Capecitabine for Patients with Advanced Pancreatic Cancer
por: Choi, Jong Gwon, et al.
Publicado: (2012)

Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis
por: Wang, Yuan, et al.
Publicado: (2016)

Enhancement of Pancreatic Cancer Therapy Efficacy by Type-1 Matrix Metalloproteinase-Functionalized Nanoparticles for the Selective Delivery of Gemcitabine and Erlotinib
por: Yin, Na, et al.
Publicado: (2020)

Report of a unique case of gemcitabine-induced radiation recall myelitis following spinal cord irradiation
por: Masson, Ingrid, et al.
Publicado: (2020)

Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy
por: Kim, Hong Jun, et al.
Publicado: (2020)

A randomized, multicenter, phase III study of gemcitabine combined with capecitabine versus gemcitabine alone as first-line chemotherapy for advanced pancreatic cancer in South Korea
por: Lee, Hee Seung, et al.
Publicado: (2017)

Ivermectin and gemcitabine combination treatment induces apoptosis of pancreatic cancer cells via mitochondrial dysfunction
por: Lee, Da Eun, et al.
Publicado: (2022)

Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
por: Lee, Kyung-Hun, et al.
Publicado: (2021)

Tumour shrinkage at 6 weeks predicts favorable clinical outcomes in a phase III study of gemcitabine and oxaliplatin with or without erlotinib for advanced biliary tract cancer
por: Kim, Seung Tae, et al.
Publicado: (2015)

Radiation recall dermatitis induced by tamoxifen during adjuvant breast cancer treatment
por: Rhee, Jiyoung, et al.
Publicado: (2014)

Anti-microbial and anti-inflammatory effects of Cheonwangbosim-dan against Helicobacter pylori-induced gastritis
por: Park, Hee-Seon, et al.
Publicado: (2020)

The anti-fibrotic effect of GV1001 combined with gemcitabine on treatment of pancreatic ductal adenocarcinoma
por: Park, Joo Kyung, et al.
Publicado: (2016)

Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
por: Bartholomeusz, Chandra, et al.
Publicado: (2011)

Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma
por: Abdel-Wahab, Reham, et al.
Publicado: (2018)

Association of the Extent of Atrophic Gastritis With Specific Dyspeptic Symptoms
por: Chung, Sook Hee, et al.
Publicado: (2015)

Fermented‐Rhus verniciflua extract ameliorate Helicobacter pylori eradication rate and gastritis
por: Kim, Seungwoo, et al.
Publicado: (2020)

Predictive role of skin rash in advanced pancreatic cancer patients treated with gemcitabine plus erlotinib: a systematic review and meta-analysis
por: Zeng, Minyan, et al.
Publicado: (2018)

A phase II trial of gemcitabine and erlotinib followed by ChemoProton therapy plus capecitabine and oxaliplatin for locally advanced pancreatic cancer
por: Sanghvi, Samrat M., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ed5nll08f4nk6t9ga85e1osjm6